Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07303881 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer

Study acronym: JACKPOT22
StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This study is a single-arm clinical trial designed to evaluate the safety and efficacy of golidocitinib in patients with refractory, immune-related hematologic toxicity in advanced lung cancer.
Trial Details
NCT Number NCT07303881
Lead Sponsor The First Affiliated Hospital of Guangzhou Medical University
Conditions
(from sponsor)		 IrAE, Hematologic Disorder, Lung Cancer (Locally Advanced or Metastatic)
Related terms Hematologic Diseases, Lung Neoplasms, Neoplasm Metastasis
Enrollment 16 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov